Vise Technologies Inc. Takes $381,000 Position in Moderna, Inc. $MRNA

Vise Technologies Inc. bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the second quarter, according to its most recent filing with the SEC. The fund bought 5,447 shares of the company’s stock, valued at approximately $381,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Assetmark Inc. increased its holdings in Moderna by 35.1% during the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after buying an additional 208 shares during the last quarter. New Mexico Educational Retirement Board boosted its stake in Moderna by 1.9% in the fourth quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock valued at $463,000 after acquiring an additional 300 shares during the last quarter. IFP Advisors Inc grew its position in shares of Moderna by 5.4% during the 4th quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock valued at $200,000 after acquiring an additional 348 shares during the period. Empowered Funds LLC increased its stake in shares of Moderna by 2.6% during the 4th quarter. Empowered Funds LLC now owns 13,732 shares of the company’s stock worth $405,000 after purchasing an additional 353 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators increased its stake in shares of Moderna by 16.9% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,640 shares of the company’s stock worth $78,000 after purchasing an additional 382 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $158.83 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $176.66. The stock has a market cap of $63.41 billion, a PE ratio of -19.88 and a beta of 0.91. The stock has a fifty day moving average of $72.29 and a 200-day moving average of $57.69.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The firm had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.13) earnings per share. Equities research analysts anticipate that Moderna, Inc. will post -6.18 earnings per share for the current year.

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the sale, the president owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the transaction, the insider owned 67,468 shares in the company, valued at $3,373,400. This trade represents a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.80% of the stock is currently owned by insiders.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Positive Phase 3 cancer-vaccine data remains the main catalyst. Moderna and Merck reported that intismeran, used with Keytruda, met key goals in the INTerpath-001 study of resected melanoma. The result is viewed as an important validation of Moderna’s mRNA technology because it reportedly showed benefit over Keytruda alone—the first positive late-stage readout for an mRNA-based cancer vaccine in this setting. Moderna’s personalized cancer vaccine shows promise
• Positive Sentiment: Analysts see a substantial opportunity. Wolfe Research estimates the melanoma and broader cancer-vaccine opportunity could reach approximately $9.2 billion, while other analysts have raised ratings and highlighted the long-term potential of intismeran. That has helped shift the investment narrative beyond Moderna’s declining COVID-19 business. MRNA Stock Jumps Past $150
• Positive Sentiment: Broader mRNA validation is supporting sentiment. The FDA’s approval of the first mRNA-based flu vaccine could improve perceptions of mRNA platforms and reinforce the value of related intellectual property, although the approval is not itself a direct Moderna product catalyst. FDA Approves First mRNA-Based Flu Vaccine
• Neutral Sentiment: Trading momentum is amplifying the move. A reported “Power Inflow” signal and unusually heavy volume indicate strong buying interest, but these technical indicators do not establish the vaccine’s long-term commercial value. Moderna Shares Rise After Trading Signal
• Negative Sentiment: Investors face significant execution and valuation risks. The cancer-vaccine evidence remains limited, and broader adoption could be constrained by manufacturing complexity, regulatory requirements, cost, competition and the need for additional data. Analysts also caution that Moderna’s pipeline and financial outlook remain challenging outside this program. Explainer on the Merck-Moderna Cancer Vaccine
• Negative Sentiment: Profit-taking and geopolitical concerns could increase volatility. Moderna previously fell as traders locked in gains after its extraordinary advance. CEO Stéphane Bancel also warned that China is investing heavily in biotechnology and mRNA, creating a potential long-term competitive threat. Moderna CEO Warns About China’s mRNA Investment

Analyst Ratings Changes

Several research firms recently commented on MRNA. Citigroup upped their price objective on Moderna from $41.00 to $60.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. William Blair upgraded Moderna from a “market perform” rating to an “outperform” rating in a research note on Wednesday, August 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a research report on Friday, June 12th. Bank of America upgraded Moderna from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 19th. Finally, Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a report on Wednesday, August 19th. Four analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Moderna currently has an average rating of “Hold” and an average price target of $74.31.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.